AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$NTLA

Intellia Therapeutics, Inc.

Price · $NTLAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $NTLA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $NTLA in the last 30 days.

Top stories · $NTLAMore →
MAY 13·Simply Wall StreetLow

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline

Intellia Therapeutics (NTLA) reported a Q1 2026 net loss of US$96.2 million on US$15.0 million revenue, similar to the previous quarter, raising questions about its path to profitability. Despite analysts projecting 64.4% annual earnings growth and profitability within three years, the company's premium P/S multiple of 29.6x and ongoing losses concern cautious investors. While a DCF fair value is significantly higher, this relies on future revenue growth and profitability, with continued dilution being a risk.

MAY 6·Barchart.com

Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying

Intellia Therapeutics (NTLA), a clinical-stage biotech firm specializing in CRISPR-based gene editing, has seen its stock drop nearly 95% from its 2021 peak due to safety concerns and lack of commercial revenue. Despite this, Cathie Wood has been steadily buying NTLA shares through her ARK ETFs, indicating long-term confidence in the high-risk, high-reward gene-editing sector. Recent positive Phase 3 results for Intellia's hereditary angioedema treatment and narrowing losses suggest a potential gradual recovery for the stock.

MAY 1·TipRanks

Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline

Intellia Therapeutics successfully raised approximately $194.6 million through a public equity offering to fund its pipeline and operations into 2028. The company plans to use these proceeds for clinical development, commercial launch preparation, new candidate research, potential acquisitions, and general corporate purposes. This financial move strengthens Intellia's balance sheet ahead of potential regulatory approval for lonvoguran ziclumeran in 2027.

News on $NTLA

All news →